|
USV, an Indian multinational healthcare company, has launched Xenia (empagliflozin and its combinations), a leading SGLT2 inhibitor, for glycaemic control, heart failure and chronic kidney care in people with type 2 diabetes. This launch strengthens USV’s presence in the Rs. 1,100 crore SGLT2i market and reinforces its leadership in oral anti-diabetes care.
USV has introduced Xenia (empagliflozin 10 mg & 25 mg), Xenia M (empagliflozin 12.5 mg + metformin 500 mg IR/1000 mg ER), and Xenia ST (empagliflozin 25 mg + sitagliptin 100 mg).
These combinations offer flexible dosing, reduced pill burden, and improved access to modern therapy, enabling early treatment to reduce diabetes complications and mortality.
Commenting on the launch, Prashant Tewari, managing director, USV said: "India has over 101 million people with type 2 diabetes and 136 million with prediabetes. With Xenia, we aim to expand access to modern diabetes care while reinforcing our leadership in the segment. USV remains committed to delivering affordable, high-quality therapies for better patient outcomes."
With the loss of exclusivity, empagliflozin and its combinations are now available at one-fifth the cost, enhancing affordability. USV’s extensive reach across metros, Tier I, II & III cities, corporate hospitals, and e-pharmacies ensures Xenia's accessibility nationwide, including rural areas.
Established in 1961, USV Private Limited is a leading Indian multinational healthcare company with a presence in 65+ countries. In India, USV holds the #1 position by prescriptions in the oral anti-diabetic and cardiology markets. Its global portfolio includes APIs, generics, branded generics, peptides, and biosimilars.
|